N-(4-aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine

N-(4-aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine (NSL-CG) is a synthetic peptide and peptidomimetic compound derived from the dipeptide cysteinylglycine. It is classified as a small molecule and has been studied experimentally for its potential antiviral activity against SARS-CoV-2. In silico studies suggest that NSL-CG may act as a dual inhibitor targeting both the replication-transcription complex and RNA-dependent RNA polymerase of SARS-CoV-2, potentially interfering with viral replication processes. The compound remains in the experimental stage with no approved indications or clinical trial phases reported[1][5][7].

Other names

N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycineGlycine, N-(4-amino-1-oxobutyl)-S-[(4-methoxyphenyl)methyl]-L-cysteinyl-N-(4-Aminobutanoyl)-S-(4-méthoxybenzyl)-L-cystéinylglycine